News & Key figures

 

Analyst coverage

Institute
Analyst
Target price
Report
Intron Health Research
Dominic Rose
47 CHF
view
Baader Bank
Amandeep Goyal
81 CHF
view
Stifel
Daniel Jelovcan
68 CHF
view

News

Press Releases

17.7.25
Xlife Sciences AG’s Portfolio Company, VERAXA Biotech AG, Takes Key Step Toward NASDAQ Listing with Filing of Form F-4
24.6.25
Xlife Sciences AG: Successful General Meeting and Growth Prospects for 2025
16.6.25
Strategic Collaboration Between Xlife Sciences AG, Huraypositive Corp., and OncoMASTER Inc. to Boost Digital Health and Precision Oncology in Asia
Archive

Ad hoc News

5.5.2025
Xlife Sciences AG confirms sustainable value development and strategic scaling of the portfolio in the 2024 Valuation Report
25.4.2025
Xlife Sciences AG publishes 2024 Annual Report: Strategic Expansion, Technological Milestones, and International Capital Market Presence
23.4.2025
From Lab to Unicorn: Xlife Sciences AG Portfolio Company VERAXA Biotech AG to merge with Voyager Acquisition Corp. listed on NASDAQ
Archive

Downloads

Financial Reports

May 5, 2025
Valuation Report 2024
April 25, 2025
Annual Report 2024
September 19, 2024
Half-Year Report 2024
April 30, 2024
Valuation Report 2023
April 23, 2024
Annual Report 2023
September 21, 2023
Half-Year Report 2023
April 27, 2023
Valuation Report 2022
April 20, 2023
Annual Report 2022
September 28, 2022
Half-Year Report 2022
May 9, 2022
Valuation Report 2021
April 29, 2022
Annual Report 2021
February 8, 2022
Interim financial statement Q3 2021 (only in german)
August 5, 2021
Semi-Annual Report 2021
Half-year results (only available in German)
May 29, 2020
Annual statement 2020

Sign up for our media releases